Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study

authors

• Rosenthal Mark
• Clement Paul
• Campone Mario
• Gil-Gil Miguel
• Degroot John
• Chinot Olivier
• Idbaih Ahmed
• Gan Hui
• Raizer Jeffrey
• Wen Patrick Yung
• Pineda Estela
• Donnet Valerie
• Mills David
• El-Hashimy Mona
• Mason Warren

keywords

• BKM120
• Buparlisib
• RGBM
• Recurrent glioblastoma

abstract

Glioblastoma relapse is associated with activation of phosphatidylinositol 3-kinase (PI3K) signalling pathway. In preclinical studies, the pan-PI3K inhibitor buparlisib showed antitumour activity in glioma models.

more information